Galmed Pharmaceuticals (GLMD) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Galmed Pharmaceuticals is broadening its horizons by expanding its drug development activities into cancer and cardiometabolic diseases, leveraging its advanced SCD1 inhibitor Aramchol, previously focused on liver disease. The company plans to explore Aramchol-based drug combinations to enhance oncology treatments and target cardiac fibrosis, with new study data expected by the end of 2024. This strategic move is spurred by recent scientific insights and an increase in funds, promising to address significant health issues affecting millions globally.
For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.
